Pegah Khosravian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pegah Khosravian has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Dhiya Altememy
Department of Pharmaceutics, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq
9 shared publications - Moosa Javdani
Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahrekord University, Shahrekord, Iran
4 shared publications Pooria Mohammadi Arvejeh
Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 shared publications- Abolfazl Barzegar
Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
2 shared publications - Alaa A. Hashim
Student Research committee, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 shared publications - Ali Amini
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 274-289
Preparation, Physicochemical Characterization and In Vitro Anticancer Evaluation of Metformin-and Celecoxib-Loaded Hyaluronic Acid-Coated Selenium Nanoparticles against Breast Cancer Cell Lines
Objective: For the treatment of breast cancer, targeted pharmaceutical delivery systems with enhanced therapeutic efficacy and fewer side effects are desperately needed. The purpose of this work was to create, physicochemically describe, and assess the anticancer activity and in vitro drug release of hyaluronic acid (HA)-coated selenium nanoparticles (SeNPs-HA) loaded with either metformin (Met) or celecoxib (CXB) against breast cancer cell lines. Methods: Chemical reduction and HA surface functionalization were used to create drug-loaded SeNPs-HA. Ultraviolet-visible (UV–Vis) spectroscopy, Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), dynamic light scattering (DLS), zeta potential analysis, energy dispersive X-ray spectroscopy (EDX), and thermogravimetric analysis (TGA) were used to characterize the nanoparticles. UV-Vis spectrophotometry was used to measure drug loading efficiency (LE), loading capacity (LC), and in vitro drug release at pH 5.5 and pH 7.4. The MTT test was used to assess the formulations' cytotoxic effects, at treatment concentrations of 222.55 mmol (Met) and 8.19 mmol (CXB), against the breast cancer cell lines MCF-7, MDA-MB-231, and 4T1 following 48 and 72 h of treatment; all experiments were performed independently at least five times (n ≥ 5). Results: The produced nanoparticles demonstrated effective drug loading, successful HA coating, and advantageous physicochemical properties. DLS analysis showed hydrodynamic diameters of 182.8 nm for bare SeNPs, increasing to 410.4 nm after HA coating, and 289.1 nm and 381.1 nm for Met-SeNPs-HA and CXB-SeNPs-HA, respectively. Zeta potential values were −23.84 mV (bare SeNPs), −16.38 mV (SeNPs-HA), −22.93 mV (Met-SeNPs-HA), and −26.24 mV (CXB-SeNPs-HA), confirming retention of a negative surface charge after coating and drug loading. While CXB-loaded SeNPs had a loading efficiency of 31.91% and a loading capacity of 86.92%, Met-loaded SeNPs demonstrated a loading efficiency of 62.21% and a loading capacity of 99.36%. HA-coated formulations decreased the first burst release and delivered a more sustained release profile at pH 5.5 and pH 7.4 compared with uncoated SeNPs; faster drug release was observed under acidic conditions. All formulations dramatically decreased the viability of MCF-7, MDA-MB-231, and 4T1 cells (P<0.001). The combined Met-SeNPs-HA+CXB-SeNPs-HA treatment showed the highest antiproliferative effect among the investigated formulations, lowering 4T1 cell viability to roughly 2.16% after 72 h. Conclusion: Met and CXB were successfully encapsulated by HA-coated SeNPs, bringing about prolonged and pH-responsive drug release as well as increased in vitro anticancer efficacy against breast cancer cell lines. These results imply that HA-functionalized SeNPs are a suitable nanocarrier for the regulated administration of Met and CXB in breast cancer treatment, and they call for additional preclinical research to assess their safety, therapeutic efficacy, and pharmacokinetic behavior.
- 7 November 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 274-289
Open AccessPreparation, Physicochemical Characterization and In Vitro Anticancer Evaluation of Metformin-and Celecoxib-Loaded Hyaluronic Acid-Coated Selenium Nanoparticles against Breast Cancer Cell Lines
Objective: For the treatment of breast cancer, targeted pharmaceutical delivery systems with enhanced therapeutic efficacy and fewer side effects are desperately needed. The purpose of this work was to create, physicochemically describe, and assess the anticancer activity and in vitro drug release of hyaluronic acid (HA)-coated selenium nanoparticles (SeNPs-HA) loaded with either metformin (Met) or celecoxib (CXB) against breast cancer cell lines. Methods: Chemical reduction and HA surface functionalization were used to create drug-loaded SeNPs-HA. Ultraviolet-visible (UV–Vis) spectroscopy, Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), dynamic light scattering (DLS), zeta potential analysis, energy dispersive X-ray spectroscopy (EDX), and thermogravimetric analysis (TGA) were used to characterize the nanoparticles. UV-Vis spectrophotometry was used to measure drug loading efficiency (LE), loading capacity (LC), and in vitro drug release at pH 5.5 and pH 7.4. The MTT test was used to assess the formulations' cytotoxic effects, at treatment concentrations of 222.55 mmol (Met) and 8.19 mmol (CXB), against the breast cancer cell lines MCF-7, MDA-MB-231, and 4T1 following 48 and 72 h of treatment; all experiments were performed independently at least five times (n ≥ 5). Results: The produced nanoparticles demonstrated effective drug loading, successful HA coating, and advantageous physicochemical properties. DLS analysis showed hydrodynamic diameters of 182.8 nm for bare SeNPs, increasing to 410.4 nm after HA coating, and 289.1 nm and 381.1 nm for Met-SeNPs-HA and CXB-SeNPs-HA, respectively. Zeta potential values were −23.84 mV (bare SeNPs), −16.38 mV (SeNPs-HA), −22.93 mV (Met-SeNPs-HA), and −26.24 mV (CXB-SeNPs-HA), confirming retention of a negative surface charge after coating and drug loading. While CXB-loaded SeNPs had a loading efficiency of 31.91% and a loading capacity of 86.92%, Met-loaded SeNPs demonstrated a loading efficiency of 62.21% and a loading capacity of 99.36%. HA-coated formulations decreased the first burst release and delivered a more sustained release profile at pH 5.5 and pH 7.4 compared with uncoated SeNPs; faster drug release was observed under acidic conditions. All formulations dramatically decreased the viability of MCF-7, MDA-MB-231, and 4T1 cells (P<0.001). The combined Met-SeNPs-HA+CXB-SeNPs-HA treatment showed the highest antiproliferative effect among the investigated formulations, lowering 4T1 cell viability to roughly 2.16% after 72 h. Conclusion: Met and CXB were successfully encapsulated by HA-coated SeNPs, bringing about prolonged and pH-responsive drug release as well as increased in vitro anticancer efficacy against breast cancer cell lines. These results imply that HA-functionalized SeNPs are a suitable nanocarrier for the regulated administration of Met and CXB in breast cancer treatment, and they call for additional preclinical research to assess their safety, therapeutic efficacy, and pharmacokinetic behavior.
- Open Access
- 21 May 2026
- Published by Elsevier in SSRN Electronic Journal
Synthesis and evaluation of the antibacterial and antioxidant activities of rutin-loaded selenium nanoparticles: integrated in vitro and molecular dynamics simulation study
The emergence of antibiotic-resistant bacteria necessitates the development of novel antimicrobial strategies targeting essential bacterial enzymes. In this study, we investigated the antibacterial and antioxidant potential of rutin-loaded selenium nanoparticles (Rut/SeNPs) through an integrated in silico and in vitro approach. Initially, molecular docking was performed against Escherichia coli DNA gyrase B (PDB: 6F86) and Topoisomerase IV (PDB: 1S14), identifying rutin as the most promising polyphenolic inhibitor, with binding energies of −8.5 and −8.4 kcal/mol, respectively. Molecular dynamics simulations (100 ns) confirmed stable complex formation, particularly with DNA gyrase B, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. Rut/SeNPs were synthesized via chemical reduction and characterized by DLS (151.3 nm, PDI = 0.22), SEM, EDX, zeta potential (−13.57 mV), and FTIR analyses, confirming successful conjugation. Antibacterial evaluation revealed significantly enhanced activity of Rut/SeNPs compared to free rutin or SeNPs alone, with minimum inhibitory concentrations(MIC) of 31.25 µg/mL against S. aureus and 62.5 µg/mL against E. coli. Furthermore, Rut/SeNPs exhibited superior antioxidant capacity (FRAP = 873.33 µM) relative to individual components, indicating synergistic redox enhancement. Collectively, these findings demonstrate that nanoformulation of rutin with selenium nanoparticles enhances its bioactivity and supports its potential as a dual-target antibacterial and antioxidant nanotherapeutic platform.
- 21 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSynthesis and evaluation of the antibacterial and antioxidant activities of rutin-loaded selenium nanoparticles: integrated in vitro and molecular dynamics simulation study
The emergence of antibiotic-resistant bacteria necessitates the development of novel antimicrobial strategies targeting essential bacterial enzymes. In this study, we investigated the antibacterial and antioxidant potential of rutin-loaded selenium nanoparticles (Rut/SeNPs) through an integrated in silico and in vitro approach. Initially, molecular docking was performed against Escherichia coli DNA gyrase B (PDB: 6F86) and Topoisomerase IV (PDB: 1S14), identifying rutin as the most promising polyphenolic inhibitor, with binding energies of −8.5 and −8.4 kcal/mol, respectively. Molecular dynamics simulations (100 ns) confirmed stable complex formation, particularly with DNA gyrase B, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. Rut/SeNPs were synthesized via chemical reduction and characterized by DLS (151.3 nm, PDI = 0.22), SEM, EDX, zeta potential (−13.57 mV), and FTIR analyses, confirming successful conjugation. Antibacterial evaluation revealed significantly enhanced activity of Rut/SeNPs compared to free rutin or SeNPs alone, with minimum inhibitory concentrations(MIC) of 31.25 µg/mL against S. aureus and 62.5 µg/mL against E. coli. Furthermore, Rut/SeNPs exhibited superior antioxidant capacity (FRAP = 873.33 µM) relative to individual components, indicating synergistic redox enhancement. Collectively, these findings demonstrate that nanoformulation of rutin with selenium nanoparticles enhances its bioactivity and supports its potential as a dual-target antibacterial and antioxidant nanotherapeutic platform.
- 18 February 2026
- Published by Maad Rayan Publishing Company in Future Natural Products
- Vol. 11 (1) , 4-9
Synergistic Effects of Acyclovir and Curcumin on Herpes Simplex Virus Type 1
Introduction: The emergence of drug-resistant viral strains has emphasized the need for natural antiviral compounds with fewer side effects. Curcumin, a natural polyphenol, exhibits antiviral, antioxidant, antitumor, and anti-inflammatory activities. Considering that drug combinations can reduce resistance development and cytotoxicity by lowering effective doses, this study aimed to evaluate the synergistic effects of curcumin combined with acyclovir against herpes simplex virus type 1 (HSV-1) in vitro. Methods: In this experimental study, the cytotoxicity of curcumin and acyclovir was assessed on Vero cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Moreover, the antiviral activity of curcumin and acyclovir alone, as well as acyclovir combined with the 10% cytotoxic concentration (CC10) of curcumin, was evaluated using MTT and 50% tissue culture infective dose assays, and the 50% inhibitory concentration (IC50) underwent calculation. Ultimately, synergistic effects were analyzed by determining viral growth inhibition percentages at various drug concentrations, and the combination index was computed using CompuSyn 1.0. Results: The CC50 values of acyclovir and curcumin were 537.7 µM and 74.44 µM, respectively. Furthermore, the IC50 values were 0.395, 12.6 µM, and 0.144 µM for acyclovir, curcumin, and the combination of acyclovir with 20 µM (CC10) curcumin, respectively. Both compounds significantly reduced viral titers individually and in combination. Finally, the combined treatment demonstrated a synergistic antiviral effect at the tested concentrations. Conclusion: Overall, curcumin had notable antiviral activity against HSV-1 in vitro and substantially enhanced acyclovir’s antiviral efficacy through synergistic interaction, suggesting potential for future clinical evaluations.
- 18 February 2026
- Published by Maad Rayan Publishing Company in Future Natural Products
- Vol. 11 (1) , 4-9
Synergistic Effects of Acyclovir and Curcumin on Herpes Simplex Virus Type 1
Introduction: The emergence of drug-resistant viral strains has emphasized the need for natural antiviral compounds with fewer side effects. Curcumin, a natural polyphenol, exhibits antiviral, antioxidant, antitumor, and anti-inflammatory activities. Considering that drug combinations can reduce resistance development and cytotoxicity by lowering effective doses, this study aimed to evaluate the synergistic effects of curcumin combined with acyclovir against herpes simplex virus type 1 (HSV-1) in vitro. Methods: In this experimental study, the cytotoxicity of curcumin and acyclovir was assessed on Vero cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Moreover, the antiviral activity of curcumin and acyclovir alone, as well as acyclovir combined with the 10% cytotoxic concentration (CC10) of curcumin, was evaluated using MTT and 50% tissue culture infective dose assays, and the 50% inhibitory concentration (IC50) underwent calculation. Ultimately, synergistic effects were analyzed by determining viral growth inhibition percentages at various drug concentrations, and the combination index was computed using CompuSyn 1.0. Results: The CC50 values of acyclovir and curcumin were 537.7 µM and 74.44 µM, respectively. Furthermore, the IC50 values were 0.395, 12.6 µM, and 0.144 µM for acyclovir, curcumin, and the combination of acyclovir with 20 µM (CC10) curcumin, respectively. Both compounds significantly reduced viral titers individually and in combination. Finally, the combined treatment demonstrated a synergistic antiviral effect at the tested concentrations. Conclusion: Overall, curcumin had notable antiviral activity against HSV-1 in vitro and substantially enhanced acyclovir’s antiviral efficacy through synergistic interaction, suggesting potential for future clinical evaluations.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Inflammation
- Vol. 2026 (1) , 7179301
Quinic and Ferulic Acid–Loaded Chitosan Nanoparticles Attenuate Experimental Ulcerative Colitis by Modulating the IL‐32/IL‐33/IL‐34 Axis and NF‐κB Signaling
Introduction: Ulcerative colitis (UC) is characterized by immune dysregulation and localized inflammation of the colonic mucosa. Despite advances in therapy, effective treatment remains difficult. This study aimed to investigate the immunomodulatory and therapeutic effects of chitosan nanoparticles (CS‐NPs) loaded with quinic acid (QA) and ferulic acid (FA) in an experimental model of UC, focusing on the IL‐32/IL‐33/IL‐34 cytokine axis and the NF‐κB signaling pathway. Methods: Eighty male Wistar rats were randomly divided into 10 groups ( n = 8 per group). Experimental acute colitis was induced in rats via intrarectal administration of 4% acetic acid (AA). After induction, the animals received CS‐NPs loaded with QA and FA for seven consecutive days. IL‐33, IL‐34, and NF‐κB mRNA expression were measured by real‐time PCR. Additionally, tissue IL‐32 levels were measured using an ELISA kit. Results: Induction of UC significantly increased IL‐32 protein levels as well as the expression of IL‐33, IL‐34, and NF‐κB. Oral administration with mesalazine, FA/QA/CS‐NPs, QA/CS‐NPs, FA/CS‐NPs, FA/QA, QA, and FA significantly decreased IL‐32 protein levels and the expression of IL‐33, IL‐34, and NF‐κB relative to the model group. Conclusion: FA/QA‐loaded CS‐NPs exhibit anti‐inflammatory effects in experimental UC, likely through modulation of the IL‐32/IL‐33/IL‐34 cytokine axis and NF‐κB signaling. These findings suggest that FA/QA/CS‐NPs may serve as a promising herbal‐based therapeutic candidate for the treatment of UC in humans.
- 1 January 2026
- Published by Wiley in International Journal of Inflammation
- Vol. 2026 (1) , 7179301
Open AccessQuinic and Ferulic Acid–Loaded Chitosan Nanoparticles Attenuate Experimental Ulcerative Colitis by Modulating the IL‐32/IL‐33/IL‐34 Axis and NF‐κB Signaling
Introduction: Ulcerative colitis (UC) is characterized by immune dysregulation and localized inflammation of the colonic mucosa. Despite advances in therapy, effective treatment remains difficult. This study aimed to investigate the immunomodulatory and therapeutic effects of chitosan nanoparticles (CS‐NPs) loaded with quinic acid (QA) and ferulic acid (FA) in an experimental model of UC, focusing on the IL‐32/IL‐33/IL‐34 cytokine axis and the NF‐κB signaling pathway. Methods: Eighty male Wistar rats were randomly divided into 10 groups ( n = 8 per group). Experimental acute colitis was induced in rats via intrarectal administration of 4% acetic acid (AA). After induction, the animals received CS‐NPs loaded with QA and FA for seven consecutive days. IL‐33, IL‐34, and NF‐κB mRNA expression were measured by real‐time PCR. Additionally, tissue IL‐32 levels were measured using an ELISA kit. Results: Induction of UC significantly increased IL‐32 protein levels as well as the expression of IL‐33, IL‐34, and NF‐κB. Oral administration with mesalazine, FA/QA/CS‐NPs, QA/CS‐NPs, FA/CS‐NPs, FA/QA, QA, and FA significantly decreased IL‐32 protein levels and the expression of IL‐33, IL‐34, and NF‐κB relative to the model group. Conclusion: FA/QA‐loaded CS‐NPs exhibit anti‐inflammatory effects in experimental UC, likely through modulation of the IL‐32/IL‐33/IL‐34 cytokine axis and NF‐κB signaling. These findings suggest that FA/QA/CS‐NPs may serve as a promising herbal‐based therapeutic candidate for the treatment of UC in humans.
- 7 October 2025
- Published by Springer Nature in BioMetals
- Vol. 39 (1) , 119-131
Impact of nano-selenium supplementation add-on sertraline on depressive symptoms and oxidative stress in patients with major depressive disorder: a triple-blind randomized controlled trial
Major depressive disorder (MDD) is a prevalent psychiatric condition associated with increased oxidative stress, which may contribute to its pathophysiology. Elevated malondialdehyde (MDA) levels and reduced total antioxidant capacity (TAC) and glutathione peroxidase (GPX) activity have been observed in individuals with MDD. Nano-selenium, a novel formulation with enhanced bioavailability and antioxidant potency compared to conventional selenium, may help modulate these oxidative stress biomarkers. In this randomized, triple-blind, placebo-controlled trial, 50 adults newly diagnosed with MDD received either nano-selenium (55 µg/day) or placebo, both alongside sertraline (50 mg/day), over a 12-week period. A total of 42 participants (21 per group) completed the study. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HDRS), and serum levels of GPX, TAC, and MDA were assessed at baseline and post-intervention. Compared to placebo, nano-selenium significantly reduced depressive symptoms (mean change: −5.09 ± 4.94; P < 0.001) and increased TAC (mean change: 0.03 ± 0.04 mmol/L; P = 0.003) and GPX levels (median change: 9.56 U/L; IQR: −7.86 to 30.31; P = 0.044). While MDA levels decreased significantly in both groups, between-group differences were not statistically significant. These findings suggest that nano-selenium may serve as a safe and effective adjunctive therapy for reducing depressive symptoms and improving antioxidant status in MDD. However, the short duration and modest sample size of this study limit generalizability. Larger, multicenter trials with extended follow-up are recommended to confirm and expand upon these results. This study was approved by the Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.REC.1402.206; June 13, 2023) and registered with the Iranian Registry of Clinical Trials (IRCT20091114002709N62; July 29, 2023). Written informed consent was obtained from all participants. Graphical abstract
- 7 October 2025
- Published by Springer Nature in BioMetals
- Vol. 39 (1) , 119-131
Impact of nano-selenium supplementation add-on sertraline on depressive symptoms and oxidative stress in patients with major depressive disorder: a triple-blind randomized controlled trial
Major depressive disorder (MDD) is a prevalent psychiatric condition associated with increased oxidative stress, which may contribute to its pathophysiology. Elevated malondialdehyde (MDA) levels and reduced total antioxidant capacity (TAC) and glutathione peroxidase (GPX) activity have been observed in individuals with MDD. Nano-selenium, a novel formulation with enhanced bioavailability and antioxidant potency compared to conventional selenium, may help modulate these oxidative stress biomarkers. In this randomized, triple-blind, placebo-controlled trial, 50 adults newly diagnosed with MDD received either nano-selenium (55 µg/day) or placebo, both alongside sertraline (50 mg/day), over a 12-week period. A total of 42 participants (21 per group) completed the study. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HDRS), and serum levels of GPX, TAC, and MDA were assessed at baseline and post-intervention. Compared to placebo, nano-selenium significantly reduced depressive symptoms (mean change: −5.09 ± 4.94; P < 0.001) and increased TAC (mean change: 0.03 ± 0.04 mmol/L; P = 0.003) and GPX levels (median change: 9.56 U/L; IQR: −7.86 to 30.31; P = 0.044). While MDA levels decreased significantly in both groups, between-group differences were not statistically significant. These findings suggest that nano-selenium may serve as a safe and effective adjunctive therapy for reducing depressive symptoms and improving antioxidant status in MDD. However, the short duration and modest sample size of this study limit generalizability. Larger, multicenter trials with extended follow-up are recommended to confirm and expand upon these results. This study was approved by the Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.REC.1402.206; June 13, 2023) and registered with the Iranian Registry of Clinical Trials (IRCT20091114002709N62; July 29, 2023). Written informed consent was obtained from all participants. Graphical abstract
- Open Access
- 1 October 2025
- Published by National Academy of Sciences of Tajikistan in Journal of Surgery and Trauma
- Vol. 13 (4) , 144-153
Investigating the Therapeutic Effects of Selenium Nanoparticles and Tannic Acid on Postoperative Peritoneal Adhesion in Rats
Introduction: Developing effective and targeted therapeutic strategies for peritonitis and postoperative abdominal adhesions is essential to mitigate severe sequelae, including intestinal obstruction and infertility. Therefore, this study aimed to evaluate the efficacy of intraperitoneally administered tannic acid and selenium nanoparticles (SeNPs) in controlling experimental intraperitoneal adhesions in rats, leveraging their ...
- 1 October 2025
- Published by National Academy of Sciences of Tajikistan in Journal of Surgery and Trauma
- Vol. 13 (4) , 144-153
Open AccessInvestigating the Therapeutic Effects of Selenium Nanoparticles and Tannic Acid on Postoperative Peritoneal Adhesion in Rats
Introduction: Developing effective and targeted therapeutic strategies for peritonitis and postoperative abdominal adhesions is essential to mitigate severe sequelae, including intestinal obstruction and infertility. Therefore, this study aimed to evaluate the efficacy of intraperitoneally administered tannic acid and selenium nanoparticles (SeNPs) in controlling experimental intraperitoneal adhesions in rats, leveraging their ...
- Open Access
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 352-360
SLOW-RELEASE DRUG DELIVERY SYSTEM FOR MESOPOROUS SILICA NANOPARTICLES LOADED WITH CELASTROL TO CONTROL ADENOCARCINOMA GASTRIC CELLS
Objective: The load of low-soluble drugs, such as celastrol (Celas) in mesoporous silica nanoparticles (MSNs), increases the solubility and physicochemical stability of the drug. This study investigated the performance of MSNs loaded with Celas to counteract adenocarcinoma gastric (AGS) cells. Methods: MSNs with amine surface modification (MSN-NH2) were prepared using the sol-gel method. MSN-NH2 were loaded with Celas and surface coated with Eudragit® RS 100 (Eud). The methods evaluated final prepared Celas@MSN-NH2/Eud as scanning electron microscope (SEM), Energy-dispersive X-ray spectroscopy (EDAX), thermal gravimetric analysis (TGA), Brunauer–Emmett–Teller (BET), Fourier-transform infrared spectroscopy (FTIR) and dynamic light scattering (DLS). Final nanoparticles were investigated for loading and release of Celas by spectrophotometric method. In vitro, the antiproliferative activity of free Celas and nanoparticles in AGS cell lines was evaluated using an MTT assay. The apoptosis rate of AGS cells was assessed according to the instructions of the FITC Annexin-V apoptosis detection kit and by flow cytometry. Results: SEM results showed particles with an approximate size of 50 nm, and XRD results proved the crystal structure of MSNs. BET and Barrett–Joyner–Halenda (BJH) plots showed the surface area above 980 m2/g and the pore size of these particles at 2.8 nm, respectively. The FTIR results demonstrated the chemical structure of nanoparticles. The loading capacity of Celas@MSN-NH2/Eud with Celas was 2.6%, and the release of Celas from the nanoparticles increased under the influence of acidic pH. Anti-proliferative activity on AGS cells was increased in growth inhibitory effect by Celas@MSN-NH2/Eud than free Celas. The IC50 and confidence intervals (CI) 95% of the Celas was 0.3756 (CI 95%:0.3207-0.44 μM), higher than that of Celas@MSN-NH2/Eud, which was 0.1456 (CI95: 0.1277-0.1668 μM) against AGS cells. Examination of cellular apoptosis also showed heightened primary apoptosis in Celas-loaded nanoparticles compared to the same Celas concentration. Conclusion: According to the obtained results, it can be said that Celas@MSN-NH2/Eud exhibited good anticancer activity against AGS cells. We conclude that using MSNs with Eud coating is suitable for Celas drug delivery to gastric cancer cells.
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 352-360
Open AccessSLOW-RELEASE DRUG DELIVERY SYSTEM FOR MESOPOROUS SILICA NANOPARTICLES LOADED WITH CELASTROL TO CONTROL ADENOCARCINOMA GASTRIC CELLS
Objective: The load of low-soluble drugs, such as celastrol (Celas) in mesoporous silica nanoparticles (MSNs), increases the solubility and physicochemical stability of the drug. This study investigated the performance of MSNs loaded with Celas to counteract adenocarcinoma gastric (AGS) cells. Methods: MSNs with amine surface modification (MSN-NH2) were prepared using the sol-gel method. MSN-NH2 were loaded with Celas and surface coated with Eudragit® RS 100 (Eud). The methods evaluated final prepared Celas@MSN-NH2/Eud as scanning electron microscope (SEM), Energy-dispersive X-ray spectroscopy (EDAX), thermal gravimetric analysis (TGA), Brunauer–Emmett–Teller (BET), Fourier-transform infrared spectroscopy (FTIR) and dynamic light scattering (DLS). Final nanoparticles were investigated for loading and release of Celas by spectrophotometric method. In vitro, the antiproliferative activity of free Celas and nanoparticles in AGS cell lines was evaluated using an MTT assay. The apoptosis rate of AGS cells was assessed according to the instructions of the FITC Annexin-V apoptosis detection kit and by flow cytometry. Results: SEM results showed particles with an approximate size of 50 nm, and XRD results proved the crystal structure of MSNs. BET and Barrett–Joyner–Halenda (BJH) plots showed the surface area above 980 m2/g and the pore size of these particles at 2.8 nm, respectively. The FTIR results demonstrated the chemical structure of nanoparticles. The loading capacity of Celas@MSN-NH2/Eud with Celas was 2.6%, and the release of Celas from the nanoparticles increased under the influence of acidic pH. Anti-proliferative activity on AGS cells was increased in growth inhibitory effect by Celas@MSN-NH2/Eud than free Celas. The IC50 and confidence intervals (CI) 95% of the Celas was 0.3756 (CI 95%:0.3207-0.44 μM), higher than that of Celas@MSN-NH2/Eud, which was 0.1456 (CI95: 0.1277-0.1668 μM) against AGS cells. Examination of cellular apoptosis also showed heightened primary apoptosis in Celas-loaded nanoparticles compared to the same Celas concentration. Conclusion: According to the obtained results, it can be said that Celas@MSN-NH2/Eud exhibited good anticancer activity against AGS cells. We conclude that using MSNs with Eud coating is suitable for Celas drug delivery to gastric cancer cells.
- Open Access
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 528-533
PLASMA CONCENTRATION OF CURCUMIN AND SELENIUM FOLLOWING ADMINISTRATION OF SLOW-RELEASE CURCUMIN-LOADED SELENIUM NANOPARTICLES
Objective: Suitable plasma concentration at the site of action is a crucial therapeutic goal, so slow-release pharmaceutical dosage forms have been very effective. This study planned to investigate the plasma concentrations of curcumin (Cur) and selenium nanoparticles (SeNPs) following the administration of a slow-release system of SeNPs loaded with Cur (SeNPs@Cur). Methods: 75 adult male rats were randomly divided into five groups. The control group received no treatment. In other groups, a single dose of 5 ml of 10% ethanol (solvent group), 0.25 mg/kg SeNPs, 50 mg/kg Cur, and 0.25 mg/kg SeNPs loaded with 50 mg/kg Cur (SeNPs@Cur) were administered intraperitoneally. Blood samples were taken on days 1, 3, and 5, and blood concentrations of SeNPs and Cur were measured by inductively coupled plasma atomic emission spectroscopy (ICP-AES) and High-performance liquid chromatography (HPLC), respectively. Results: The concentration of Cur in the Cur group was less than five µg on day 1 and gradually decreased over 5 d to zero. The blood concentration of Cur was approximately 15 µg on day 1 in the SeNPs@Cur group, then decreased until the 3rd day, and finally remained at a constant level of 5 µg on the 5th d. Selenium concentration decreased in the SeNPs group, from 160 µg on day 1 to 100 µg on day 5. Selenium concentration in the SeNPs@Cur group was 180 µg on the first day, then decreased to 110 µg on the fifth day. SeNPs@Cur maintained a plasma curcumin level of 5 µg on day 5 compared to undetectable levels in the Cur group. Conclusion: This study showed that the intraperitoneal administration of SeNPs@Cur, compared to the administration of free Cur, initially causes a high serum concentration and a loading dose, which continues with the slow release, increasing and maintaining the Cur serum level in the long-term treatment period.
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 528-533
Open AccessPLASMA CONCENTRATION OF CURCUMIN AND SELENIUM FOLLOWING ADMINISTRATION OF SLOW-RELEASE CURCUMIN-LOADED SELENIUM NANOPARTICLES
Objective: Suitable plasma concentration at the site of action is a crucial therapeutic goal, so slow-release pharmaceutical dosage forms have been very effective. This study planned to investigate the plasma concentrations of curcumin (Cur) and selenium nanoparticles (SeNPs) following the administration of a slow-release system of SeNPs loaded with Cur (SeNPs@Cur). Methods: 75 adult male rats were randomly divided into five groups. The control group received no treatment. In other groups, a single dose of 5 ml of 10% ethanol (solvent group), 0.25 mg/kg SeNPs, 50 mg/kg Cur, and 0.25 mg/kg SeNPs loaded with 50 mg/kg Cur (SeNPs@Cur) were administered intraperitoneally. Blood samples were taken on days 1, 3, and 5, and blood concentrations of SeNPs and Cur were measured by inductively coupled plasma atomic emission spectroscopy (ICP-AES) and High-performance liquid chromatography (HPLC), respectively. Results: The concentration of Cur in the Cur group was less than five µg on day 1 and gradually decreased over 5 d to zero. The blood concentration of Cur was approximately 15 µg on day 1 in the SeNPs@Cur group, then decreased until the 3rd day, and finally remained at a constant level of 5 µg on the 5th d. Selenium concentration decreased in the SeNPs group, from 160 µg on day 1 to 100 µg on day 5. Selenium concentration in the SeNPs@Cur group was 180 µg on the first day, then decreased to 110 µg on the fifth day. SeNPs@Cur maintained a plasma curcumin level of 5 µg on day 5 compared to undetectable levels in the Cur group. Conclusion: This study showed that the intraperitoneal administration of SeNPs@Cur, compared to the administration of free Cur, initially causes a high serum concentration and a loading dose, which continues with the slow release, increasing and maintaining the Cur serum level in the long-term treatment period.
- Open Access
- 12 August 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 785
Impact of Nano-Selenium supplementation on the JAK/STAT signaling pathway in major depressive disorder: a Triple-Blind, randomized controlled trial
Major depressive disorder (MDD) is a prevalent mental health condition, wherein the JAK/STAT signaling pathway serves as a potent cellular mechanism implicated in its pathophysiology. Increased expression of JAK2, STAT3, and subsequently IDO1 genes appears to be linked to depressive symptoms. With their antioxidant capabilities and improved absorption due to the nano formula, selenium nanoparticles could potentially modulate this molecular pathway. This study aimed to assess the impact of nano-selenium supplementation on the expression of JAK2, STAT3, and IDO1 genes in patients with MDD. A triple-blind, randomized, placebo-controlled trial was conducted at the Psychosomatic Clinic of Imam Khomeini Hospital Complex. A total of 50 participants, newly diagnosed with MDD were randomized to either a nano-selenium (55 µg/day) or placebo group for 12 weeks. All participants were receiving their standard treatment (sertraline 50 mg/day). Blood samples were collected at baseline and post-intervention to measure the gene expression using RT-qPCR. At the end of the study, both groups showed reductions in JAK2 and STAT3 relative gene expression after 12 weeks (P < 0.05). Although the reduction was more in the nano-selenium group, the between-group differences were not statistically significant. This study is the first to examine nano-selenium as a novel potential adjunct treatment for MDD. Though the degree of reduction in JAK2 and STAT3 levels was greater within the nano-selenium group, it appears that additional investigations are needed to elucidate its effects. The research received approval from the Research Ethics Committees of Iran University of Medical Sciences (Approval ID: IR IUMS.REC.1402.206, dated 2023-06-13) and was duly registered with the Iranian Registry of Clinical Trials (IRCT; registration number: IRCT20091114002709N62, dated 2023-07-29).
- 12 August 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 785
Open AccessImpact of Nano-Selenium supplementation on the JAK/STAT signaling pathway in major depressive disorder: a Triple-Blind, randomized controlled trial
Major depressive disorder (MDD) is a prevalent mental health condition, wherein the JAK/STAT signaling pathway serves as a potent cellular mechanism implicated in its pathophysiology. Increased expression of JAK2, STAT3, and subsequently IDO1 genes appears to be linked to depressive symptoms. With their antioxidant capabilities and improved absorption due to the nano formula, selenium nanoparticles could potentially modulate this molecular pathway. This study aimed to assess the impact of nano-selenium supplementation on the expression of JAK2, STAT3, and IDO1 genes in patients with MDD. A triple-blind, randomized, placebo-controlled trial was conducted at the Psychosomatic Clinic of Imam Khomeini Hospital Complex. A total of 50 participants, newly diagnosed with MDD were randomized to either a nano-selenium (55 µg/day) or placebo group for 12 weeks. All participants were receiving their standard treatment (sertraline 50 mg/day). Blood samples were collected at baseline and post-intervention to measure the gene expression using RT-qPCR. At the end of the study, both groups showed reductions in JAK2 and STAT3 relative gene expression after 12 weeks (P < 0.05). Although the reduction was more in the nano-selenium group, the between-group differences were not statistically significant. This study is the first to examine nano-selenium as a novel potential adjunct treatment for MDD. Though the degree of reduction in JAK2 and STAT3 levels was greater within the nano-selenium group, it appears that additional investigations are needed to elucidate its effects. The research received approval from the Research Ethics Committees of Iran University of Medical Sciences (Approval ID: IR IUMS.REC.1402.206, dated 2023-06-13) and was duly registered with the Iranian Registry of Clinical Trials (IRCT; registration number: IRCT20091114002709N62, dated 2023-07-29).
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 22 (7) , 956-967
Improved Therapeutic Efficacy: Liposome-Coated Mesoporous Silica Nanoparticles Delivering Thymoquinone to MCF-7 Cells
Background: Breast cancer remains a significant global health challenge, with thymoquinone showing promise as a therapeutic agent, but hindered by poor solubility. Objective: This study aimed to enhance TQ delivery to MCF-7 breast cancer cells using mesitylene- mesoporous silica nanoparticles coated with liposomes, designed for controlled drug release. Methods: Nanoparticles were synthesized using the sol-gel method and coated with phosphatidylserine- cholesterol liposomes. Different nanocharacterization techniques and in vitro assays were employed to assess the drug release kinetics, cellular uptake, cytotoxicity, and apoptosis. Results: The nanoparticles exhibited favorable properties, including a large pore size of 3.6 nm, a surface area of 248.96 m2/g, and a hydrodynamic size of 171.571 ± 8.342 nm with a polydispersity index of 0.182 ± 0.017, indicating uniformity and stability. The successful lipid bilayer coating was confirmed by a zeta potential shift from +6.25 mV to -5.65 mV. The coated nanoparticles demonstrated a slow and sustained drug release profile, with cellular uptake of FITC-formulated nanoparticles being approximately 5-fold higher than free FITC (P < 0.0001). Cytotoxicity assays revealed a significant reduction in cell viability (P < 0.0001), reaching an IC50 value of 25 μM at 48 hours. Apoptosis rates were significantly higher in cells treated with the formulated TQ compared to the free drug and control at both 24 and 48 hours (P < 0.0001). Conclusion: This nanoformulation significantly enhanced TQ delivery, offering a promising strategy for targeted breast cancer therapy. Further preclinical studies are recommended to advance this approach in cancer treatment.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 22 (7) , 956-967
Improved Therapeutic Efficacy: Liposome-Coated Mesoporous Silica Nanoparticles Delivering Thymoquinone to MCF-7 Cells
Background: Breast cancer remains a significant global health challenge, with thymoquinone showing promise as a therapeutic agent, but hindered by poor solubility. Objective: This study aimed to enhance TQ delivery to MCF-7 breast cancer cells using mesitylene- mesoporous silica nanoparticles coated with liposomes, designed for controlled drug release. Methods: Nanoparticles were synthesized using the sol-gel method and coated with phosphatidylserine- cholesterol liposomes. Different nanocharacterization techniques and in vitro assays were employed to assess the drug release kinetics, cellular uptake, cytotoxicity, and apoptosis. Results: The nanoparticles exhibited favorable properties, including a large pore size of 3.6 nm, a surface area of 248.96 m2/g, and a hydrodynamic size of 171.571 ± 8.342 nm with a polydispersity index of 0.182 ± 0.017, indicating uniformity and stability. The successful lipid bilayer coating was confirmed by a zeta potential shift from +6.25 mV to -5.65 mV. The coated nanoparticles demonstrated a slow and sustained drug release profile, with cellular uptake of FITC-formulated nanoparticles being approximately 5-fold higher than free FITC (P < 0.0001). Cytotoxicity assays revealed a significant reduction in cell viability (P < 0.0001), reaching an IC50 value of 25 μM at 48 hours. Apoptosis rates were significantly higher in cells treated with the formulated TQ compared to the free drug and control at both 24 and 48 hours (P < 0.0001). Conclusion: This nanoformulation significantly enhanced TQ delivery, offering a promising strategy for targeted breast cancer therapy. Further preclinical studies are recommended to advance this approach in cancer treatment.